Skip to main content
. Author manuscript; available in PMC: 2012 Apr 15.
Published in final edited form as: Cancer Res. 2011 Apr 12;71(8):3009–3017. doi: 10.1158/0008-5472.CAN-10-2510

Figure 2.

Figure 2

Performance of the signature. A.) Boxplots representing the distribution of MALDI scores from patients of the validation cohort (n=60). Patients with (n=40) and without (n=20) lung cancer were analyzed. Weighted compound score was generated based on the weighted flexible compound covariate method (WFCCM). The 9 candidate features (m/z) were reduced to one summarized feature to build MALDI score for each patient. B.) Receiver-operator characteristic curves demonstrating performance of the signature to classify patients with and without cancer in the published cohort (solid line) and in the validation cohort (dotted line). AUC, area under the curve.